Funding opportunities related to SARS-CoV-2/COVID-19.
Last updated: January 11, 2021 2:30 PM.
GrantForward Covid-19 list of opportunities
GrantForward is providing free access to available coronavirus-related funding calls. The list is updated on a daily basis https://www.grantforward.com/grant-covid#
Agency for Healthcare Research and Quality (AHRQ)
NEW AHRQ Releases Two Future Funding Opportunities for COVID-19 Responsiveness
AHRQ has released two Notices of Intent for upcoming funding opportunities designed to support studies evaluating health system and healthcare professional responsiveness to COVID-19. The agency plans to publish notices calling for both urgent revision supplements to existing AHRQ grants, and for novel high-impact studies to be funded through the R01 mechanism.
- Competitive revision supplements for existing AHRQ projects should “capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the on-going research to develop high-impact new knowledge concerning COVID-19.” AHRQ expects to make at least $2.5 million available for these supplements and will release the full solicitation in April 2020.
- For new studies related to COVID-19, AHRQ is interested in “innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic,” with a particular focus on digital health innovation and meeting the needs of vulnerable populations. AHRQ expects to dedicate $5 million to this program. A full solicitation will be released in early May 2020, with an expected deadline in June 2020.
Air Force Office of Sponsored Programs
Guidance for Coronavirus Disease 2019 (COVID-19) No Cost Extensions (NCEs): https://afresearchlab.com/afosr-covid
American Heart Association
The American Heart Association is offering fast-tracked research grants for short-term projects that can turn around results within 9-12 months to better understand the diagnosis, prevention, treatment and clinical management of COVID-19 as it relates to heart and brain health. Application and more information.
CDC
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
DOE
DOE Office of Science Memorandum to Applicants and Awardees
Health and Human Services (HHS) Office of Biomedical Advanced Research and Development Authority (BARDA)
The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), issued the BAA, BAA-18-100-SOL-00003-Amendment 13, to solicit proposals for advanced development and licensure of COVID-19 diagnostics, vaccines, or medicines such as therapeutics or antivirals.
HHS BARDA has revised its Broad Agency Announcement (BAA) to only accept proposals and white papers in areas relevant to the study of COVID-19.
Areas of interest include:
- AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
- AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
- AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
- AOI 8.3 COVID-19 Vaccine
- AOI 9.2 COVID-19 Therapeutics
- AOI 9.3 Immunomodulators or therapeutics targeting lung repair
- AOI 9.5 Pre-exposure and post-exposure prophylaxis
- AOI 10 Respiratory protective devices
- AOI 11 Ventilators
- AOI 17 Advanced Manufacturing Technologies
NIH
- NIH Release update COVID-19 Website 1/11/21
- In response to the COVID-19 crisis, NIBIB has released multiple Notices of Special Interest. This includes: administrative supplements and emergency competitive revisions funding for current grantees; SBIR/STTR opportunities; and investigator-initiated research opportunities. Current grantees and new applicants are encouraged to apply immediately. The goal is to support proposals that accelerate research, translation, and commercialization of technologies relevant to COVID-19. Researchers can read NIBIB Director Bruce Tromberg’s message on how bioengineers can help thwart the COVID-19 pandemic.
Additional information can be found on the NOSIs FAQs page. - Notice of Early Expiration of Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV), NOT-AI-20-030
(NOT-AI-20-040) - Late Application Policy: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-091.html
- Urgent Competitive Revisions to NIGMS Grants to Address the Coronavirus Pandemic https://loop.nigms.nih.gov/2020/03/urgent-competitive-revisions-to-nigms-grants-to-address-the-coronavirus-pandemic/
- Memorandum on Interim Guidance for Clinical Trial Activities Affected by the Novel Coronavirus
- NIAID’s Multi-Pronged Response to the COVID-2019 Outbreak
- NIH Guide for Grants and Contracts - search results for "2019-nCoV"
- NIAID and NIGMS have issued a Notice of Special Interest (NOSI)
- Applications must be submitted using FOA PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant. Further details here:
- NIH grantees seeking additional funds for research responsive to the 2019-nCoV outbreak that falls within the scope of an ongoing grant may apply for an administrative supplement under NIH PA-18-591, Administrative Supplements to Existing NIH Grants and Cooperative Agreements FOA (https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html ).
- Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19 (3-16-20)
- Flexibilities for Assured Institutions for Activities of Institutional Animal Care and Use Committees (IACUCs) Due to COVID-19 (NOT-OD-20-088) (03-16-20)
- If you are a grantee currently supported by active NIH funding, you may be eligible to apply for an administrative supplement to support SARS-CoV-2/COVID-2019 research. Contact your program officer to discuss if this may be an option for you. If your proposed research on SARS-CoV-2/COVID-2019 is within the scope of your current grant, an administrative supplement is your best option to obtain additional funding. You should apply using the parent administrative supplement FOA PA-18-591.
NSF
- NSF has developed a new website for the research community with detailed guidance on the Coronavirus (COVID-19). This includes guidance for awardee organizations, researchers and reviewers of NSF proposals. This website will be updated with new guidance.
- Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19) - 3/5/2020
- Rapid Response Research (RAPID) Funding Mechanism
- Requests for RAPID proposals - up to $200K and one year in duration. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to rapid-covid19@nsf.gov.
- Existing funding opportunities
- FAQs: https://www.nsf.gov/pubs/2020/nsf20053/nsf20053.jsp
- NSF Guidance for Major Facilities and Contracts Regarding COVID-19
Office of Management and Budget (OMB)
OMB has issued a memo providing “Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly Impacted by the Novel Coronavirus (COVID-19)".